Autoimmune haemolytic anaemia treated by therapeutic plasma exchange and retuximab: A case report

Autoimmune haemolytic anaemia (AIHA) is an uncommon disorder characterized by shortened red blood cell (RBC) survival and the presence of autoantibodies directed against autologous RBCs. It presents with anaemia, jaundice, and splenomegaly with reticulocytosis, unconjugated hyperbilirubinaemia, and direct antiglobulin test (DAT) positivity.' AIHA has an estimated incidence of 1—3 cases per 100,000 subjects per year, a prevalence of 17:100,000 and a mortality rate of 11%.' AIHA is classified as warm AIHA (75.0% of all AIHA cases), cold AIHA (about 15.0%), and mixed type AIHA (less than 5.0%), based on the thermal range of autoantibodies involved in the pathogenesis.6 It can be idiopathic (50.0%) or secondary to lymphoproliferative syndromes (20.0%), autoimmune diseases (20.0%), infections, tumors and drugs.’ The laboratory diagnosis of AIHA depends on the result of direct antiglobulin test (DAT) which shows positivity with anti-IgG (usually in warm AIHA) and/or anti-C3d (usually in cold AIHA) antisera, and also the presence of laboratory findings supporting hemolysis such as increase of serum lactate dehydrogenase (LDH), reticulocytosis and spherocytosis in peripheral blood smears.‘ The treatment of AIHA is still not evidence-based. The first-line therapy for warm AIHA is corticosteroids, which are effective in 70.0-85.0% of patients and should be slowly tapered over a time period of 6-12 months. For refractory/relapsed cases, the current sequence of second-line therapy is splenectomy (effective approx. in 2 out of 3 cases but with a presumed cure rate of up to 20.0%), rituximab (effective in approx. 80.0-90.0% of cases), and thereafter any of the immunosuppressive drugs (azathioprine, cyclophosphamide, cyclosporin, mycophenolate mofetil). Additional therapies are intravenous immunoglobulins, danazol, plasma-exchange, and alemtuzumab and high-dose cyclophosphamide as last resort option.’ Most of the immunosuppressive drugs have many deleterious side-effects and the onset of action is slow. Splenectomy carries the risk of an overwhelming post splenectomy sepsis.‘ Rituximab (so called “medical splenectomy”) is an effective second-line therapy, can work quickly with lasting effects, providing high initial response rates up to 87.0% and prolonged disease free survivals of 56.0% up to 2 years with reduced adverse reactions.‘ ' For warm AIHA, rituximab therapy is considered as a second line option as monotherapy or combined therapy. It can also be used as a first line therapy in combination with steroids for newly diagnosed patients. ' Another option, with